Diuretics for Postpartum High Blood Pressure in Preeclampsia
- Registration Number
- NCT02163655
- Lead Sponsor
- Instituto Materno Infantil Prof. Fernando Figueira
- Brief Summary
The purpose of this study is to determine if furosemide administered after the first 24 hours of delivery, in women with severe peeclampsia and eclampsia accelerates high blood pressure control and diminishes hospital stay.
- Detailed Description
A placebo-controlled study that will be conducted including 120 postpartum women with severe preeclampsia . Women who are previosuly diuretic users, with renal impairment, hemodynamic instability or with contraindications to diuretic use will be excluded. Informed consent will be obtained from all participants . Patients will be randomized to receive furosemide ( 40mg orally every twenty-four hours ) or placebo for maximum of five days. The variables are systolic and diastolic blood pressure, frequency of very high blood pressure, need for maintenance of antihypertensive therapy , number of antihypertensive agents used to control blood pressure , urine output , length of hospital stay , adverse effects and maternal complications . Except for the study drug, patients will receive all care and monitoring according to the hospital protocol and decision to initiate or modify antihypertensive therapy will be defined by the attending physician, as well as the decision to discharge. If the patient is discharged before five days of the protocol drug, this drug will be stopped. Teh patients may decide to leave the study at any moment. Data will be collected by researches daily. Plan statistical analysis will be performed using the public domain program Epi Info 7.0 and the mean and dispersion measures for numerical variables will be calculated. To compare means obtained every day and between groups will be used analysis of variance ( ANOVA ) . Nominal variables were compared using the X2 test or Fisher if necessary. Be considered significant at p \< 0,05. The risk ratio (RR) is calculated as a measure of the relative risk for the different outcomes , according to furosemide or placebo
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 120
- Preeclampsia
- Urine output > 50ml/h
- End of postpartum magnesium sulphate
- Cronic hypertension
- Bloor pressure < 140mmHg and < 90mmHg
- Diuretic use
- Renal impairment
- Diabetes, sickle cell disease ou rheumatologic disease
- Hemodinamic instability
- Potassium < 3mEq/L
- Contraindications for fusoremide use
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description PLACEBO Placebo PLACEBO: placebo, oral, every 24 hours for maximum 5 days FUROSEMIDE FUROSEMIDE FUROSEMIDE: 20mg furosemide, oral, every 24 hours for maximum 5 days
- Primary Outcome Measures
Name Time Method Mean blood pressure from 24 hours after delivery to first 15 days of delivery
- Secondary Outcome Measures
Name Time Method Maintenance of antihypertensive therapy From 24 hours up to 15 days of delivery Number of antihypertensive agents used to control blood pressure at hospital discharge; time elapsed to control blood pressure; daily urine output; reduction of edema; length of hospital stay; frequency of adverse effects: hypokalemia, polydipsia, headache, mental confusion, muscle pain, tetany, muscle weakness, heart rhythm disturbances and gastrointestinal symptoms; frequency of maternal complications: imminent eclampsia, eclampsia, infection, bleeding manifestations, shock and maternal death.
frequency of maternal complications From 24 hours up to 15 days after delivery Frequency of imminent eclampsia, eclampsia, infection, bleeding manifestations, shock and maternal death.
postpartum hospital stay from 24 hours after delivery to 15 days Time until discharge of the hospital
frequency of adverse effects From 24 hours to 15 days after delivery Presence of hypokalemia, polydipsia, headache, mental confusion, muscle pain, tetany, muscle weakness, heart rhythm disturbances and gastrointestinal symptoms;
Trial Locations
- Locations (1)
IMIP
🇧🇷Recife, Pernambuco, Brazil